Camidge R, et al. Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: first report of a phase 3 trial (ALTA-1L). IASLC 2018, abstract PL02.03.
CDK4/6-remmers bij gemetastaseerd HR+, HER2- mammacarcinoom
mei 2019 | Borstkanker